5U6V

X-ray crystal structure of 1,2,3-triazolobenzodiazepine in complex with BRD2(D2)

Summary for 5U6V

• Entry DOI: 10.2210/pdb5u6v/pdb
• Descriptor: Bromodomain-containing protein 2, 5-[7-(4-chlorophenyl)-1-methyl-6,7-dihydro-5H-[1,2,3]triazolo[1,5-d][1,4]benzodiazepin-9-yl]pyridin-2-amine, 1,2-ETHANEDIOL, ... (4 entities in total)
• Functional Keywords: bromodomain, benzodiazepine, epigenetics, transcription-transcription inhibitor complex, transcription/transcription inhibitor
• Biological source: Homo sapiens (Human)
• Cellular location: Nucleus : P25440
• Total number of polymer chains: 1
• Total formula weight: 13628.02

Authors

Hatfaludi, T.,Sharp, P.P.,Garnier, J.-M.,Burns, C.J.,Czabotar, P.E. (deposition date: 2016-12-09, release date: 2017-12-13, Last modification date: 2024-03-06)

Primary citation

Sharp, P.P.,Garnier, J.M.,Hatfaludi, T.,Xu, Z.,Segal, D.,Jarman, K.E.,Jousset, H.,Garnham, A.,Feutrill, J.T.,Cuzzupe, A.,Hall, P.,Taylor, S.,Walkley, C.R.,Tyler, D.,Dawson, M.A.,Czabotar, P.,Wilks, A.F.,Glaser, S.,Huang, D.C.S.,Burns, C.J.
Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors.
ACS Med Chem Lett, 8:1298-1303, 2017

PubMed Abstract: A number of diazepines are known to inhibit bromo- and extra-terminal domain (BET) proteins. Their BET inhibitory activity derives from the fusion of an acetyl-lysine mimetic heterocycle onto the diazepine framework. Herein we describe a straightforward, modular synthesis of novel 1,2,3-triazolobenzodiazepines and show that the 1,2,3-triazole acts as an effective acetyl-lysine mimetic heterocycle. Structure-based optimization of this series of compounds led to the development of potent BET bromodomain inhibitors with excellent activity against leukemic cells, concomitant with a reduction in c- expression. These novel benzodiazepines therefore represent a promising class of therapeutic BET inhibitors.

PubMed: 29259751
DOI: 10.1021/acsmedchemlett.7b00389

Experimental method

X-RAY DIFFRACTION (1.775 Å)